Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novavax nets $36.1mm with private placement

Executive Summary

Novavax (vaccines and drug delivery technologies), which raised $20mm through a private financing last month, has now netted $36.1mm from a private placement of 5.2mm common shares at $7.30 each (a 12% premium). Rodman & Renshaw acted as placement agent for the transaction. This month Novavax also signed a deal with Bharat Biotech International to develop a vaccine for the avian flu.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Liposomes
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies